Pancreatic Cancer Research

ResearcherUniversität UlmNo recent work listed

Anna-Laura Kretz

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5018378740. Sources: OpenAlex.

Their work

Papers
4 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper

Papers 4

  1. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death. First author DOI 10.21873/anticanres.15416↗
  2. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Co-author DOI 10.3390/cancers10030077↗
  3. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/ijms19103219↗
  4. CDK9 is a prognostic marker and therapeutic target in pancreatic cancer. Co-author DOI 10.1177/1010428317694304↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johannes Lemke · 4 shared papers, 2017–2021 · strength 0.40
  2. Jan-Philipp Ruff · 2 shared papers, 2018–2021 · strength 0.24
  3. Silvia von Karstedt · 2 shared papers, 2018 · strength 0.18
  4. Benno Traub · 1 shared paper, 2021 · strength 0.16
  5. Marko Kornmann · 1 shared paper, 2021 · strength 0.16
  6. Anna Trauzold · 1 shared paper, 2018 · strength 0.09
  7. Balbina García-Reyes · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.